Hi Valuesnatcher. If the growth story remains intact over next...

Hi Valuesnatcher.
If the growth story remains intact over next two to three years, 30-35 cents is also not a bad entry point. I still think it is the shorters covering now and this may test 25 cents again so will give a good entry point.
I would advise you to watch Robert Grey's interview with Alan Kohler on Eureka TV (join free) . He is confident of US revenue doubling every year for next three years. They have some good competitive advantages although I would stop short of calling it a moat.
Lots of sites and software integration should follow for a number of them.
Sitting is the key here IMO. Growth company in health care, earnings are subject to fluctuation due to R and D investments. Conservative accounting: factory costs and R and D all expensed when Factory could have been capitalised.